Arcellx, Inc.

NasdaqGS ACLX

Arcellx, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 574.25 M

Arcellx, Inc. Cash and Short-Term Investments is USD 574.25 M for the quarter ending September 30, 2024, a 30.60% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Arcellx, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 439.72 M, a 56.60% change year over year.
Arcellx, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 280.78 M, a 114.04% change year over year.
Arcellx, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 131.18 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqGS: ACLX

Arcellx, Inc.

CEO	Mr. Rami Elghandour
IPO Date	Feb. 4, 2022
Location	United States
Headquarters	25 West Watkins Mill Road
Employees	130
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Key trends

Past 5 years